135 related articles for article (PubMed ID: 25989626)
1. The unbinding studies of vascular endothelial growth factor receptor-2 protein tyrosine kinase type II inhibitors.
Kang CM; Liu DQ; Wang XY; Yu RL; Lv YT
J Mol Graph Model; 2015 Jun; 59():130-5. PubMed ID: 25989626
[TBL] [Abstract][Full Text] [Related]
2. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
[TBL] [Abstract][Full Text] [Related]
3. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
Zhao H; Huang D; Caflisch A
ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
[TBL] [Abstract][Full Text] [Related]
4. De novo design of VEGFR-2 tyrosine kinase inhibitors based on a linked-fragment approach.
Liu YZ; Wang XL; Wang XY; Yu RL; Liu DQ; Kang CM
J Mol Model; 2016 Sep; 22(9):222. PubMed ID: 27558799
[TBL] [Abstract][Full Text] [Related]
5. Unbinding pathways of VEGFR2 inhibitors revealed by steered molecular dynamics.
Capelli AM; Costantino G
J Chem Inf Model; 2014 Nov; 54(11):3124-36. PubMed ID: 25299731
[TBL] [Abstract][Full Text] [Related]
6. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.
Du J; Lei B; Qin J; Liu H; Yao X
J Mol Graph Model; 2009 Jan; 27(5):642-54. PubMed ID: 19081278
[TBL] [Abstract][Full Text] [Related]
7. Identification of type-II inhibitors using kinase structures.
Lovering F; McDonald J; Whitlock GA; Glossop PA; Phillips C; Bent A; Sabnis Y; Ryan M; Fitz L; Lee J; Chang JS; Han S; Kurumbail R; Thorarensen A
Chem Biol Drug Des; 2012 Nov; 80(5):657-64. PubMed ID: 22759374
[TBL] [Abstract][Full Text] [Related]
8. Structure-based identification of potent VEGFR-2 inhibitors from in vivo metabolites of a herbal ingredient.
Dash R; Junaid M; Mitra S; Arifuzzaman M; Hosen SMZ
J Mol Model; 2019 Mar; 25(4):98. PubMed ID: 30904971
[TBL] [Abstract][Full Text] [Related]
9. Computational study on the unbinding pathways of B-RAF inhibitors and its implication for the difference of residence time: insight from random acceleration and steered molecular dynamics simulations.
Niu Y; Li S; Pan D; Liu H; Yao X
Phys Chem Chem Phys; 2016 Feb; 18(7):5622-9. PubMed ID: 26862741
[TBL] [Abstract][Full Text] [Related]
10. Assessing an ensemble docking-based virtual screening strategy for kinase targets by considering protein flexibility.
Tian S; Sun H; Pan P; Li D; Zhen X; Li Y; Hou T
J Chem Inf Model; 2014 Oct; 54(10):2664-79. PubMed ID: 25233367
[TBL] [Abstract][Full Text] [Related]
11. Molecular simulation studies to reveal the binding mechanisms of shikonin derivatives inhibiting VEGFR-2 kinase.
Munni YA; Ali MC; Selsi NJ; Sultana M; Hossen M; Bipasha TH; Rahman M; Uddin MN; Hosen SMZ; Dash R
Comput Biol Chem; 2021 Feb; 90():107414. PubMed ID: 33191109
[TBL] [Abstract][Full Text] [Related]
12. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
Rathi E; Kumar A; Kini SG
J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
[TBL] [Abstract][Full Text] [Related]
13. 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.
Kiselyov AS; Semenova M; Semenov VV; Piatnitski E
Bioorg Med Chem Lett; 2006 Mar; 16(6):1726-30. PubMed ID: 16364640
[TBL] [Abstract][Full Text] [Related]
14. Exploration of structural requirements for the inhibition of VEGFR-2 tyrosine kinase: Binding site analysis of type II, 'DFG-out' inhibitors.
Modi SJ; Kulkarni VM
J Biomol Struct Dyn; 2022 Aug; 40(12):5712-5727. PubMed ID: 33459187
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore based 3D-QSAR modeling and free energy analysis of VEGFR-2 inhibitors.
Rajagopalan M; Balasubramanian S; Ramaswamy A; Mathur PP
J Enzyme Inhib Med Chem; 2013 Dec; 28(6):1236-46. PubMed ID: 23061928
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib: from charge-density studies to interaction with proteins.
Malińska M; Jarzembska KN; Goral AM; Kutner A; Woźniak K; Dominiak PM
Acta Crystallogr D Biol Crystallogr; 2014 May; 70(Pt 5):1257-70. PubMed ID: 24816095
[TBL] [Abstract][Full Text] [Related]
17. LEADOPT: an automatic tool for structure-based lead optimization, and its application in structural optimizations of VEGFR2 and SYK inhibitors.
Li GB; Ji S; Yang LL; Zhang RJ; Chen K; Zhong L; Ma S; Yang SY
Eur J Med Chem; 2015 Mar; 93():523-38. PubMed ID: 25743214
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinases.
Nakamura H; Sasaki Y; Uno M; Yoshikawa T; Asano T; Ban HS; Fukazawa H; Shibuya M; Uehara Y
Bioorg Med Chem Lett; 2006 Oct; 16(19):5127-31. PubMed ID: 16893647
[TBL] [Abstract][Full Text] [Related]
19. Development and strategies of VEGFR-2/KDR inhibitors.
Huang L; Huang Z; Bai Z; Xie R; Sun L; Lin K
Future Med Chem; 2012 Sep; 4(14):1839-52. PubMed ID: 23043480
[TBL] [Abstract][Full Text] [Related]
20. Discovery of potent vascular endothelial growth factor receptor-2 inhibitors.
Papakyriakou A; Katsarou ME; Belimezi M; Karpusas M; Vourloumis D
ChemMedChem; 2010 Jan; 5(1):118-29. PubMed ID: 19921722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
